Fifth Industry-Wide Trial Master File Reference Model Survey is Now Open
Make sure your perspective is heard, and get valuable insights and data for your TMF improvement initiatives
Make sure your perspective is heard, and get valuable insights and data for your TMF improvement initiatives. An outgrowth of the volunteer TMF Reference Model initiative, this survey is designed to provide year-over-year TMF details from sponsors, CROs, inspectors, and sites, for both paper and electronic TMF management. The intent is to identify TMF trends, assess changes in industry directions, and measure the impact of TMF models. Survey link: https://www.surveymonkey.com/s/TMF2015.
Survey completion takes ten minutes or less, depending on your organization. All respondents who complete the survey and provide contact details will be sent the results; no respondent is identified in the results.
The TMF Survey has been developed by volunteer members of the TMF Reference Model initiative. Information about us can be found at the end of the survey, and also at: http://tmfrefmodel.com.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
